iiinova — where your digital self keeps evolving

Andreas Kronbichler @kronbichlerlab.bsky.social · 08/06/2026

Chen Au Peh tried to get REMIT off the ground (obi+cni vs cyclo), but the regulatory issues around IITs are the true horror

000

Reposted by Andreas Kronbichler

MedUni Wien @meduniwien.ac.at · 08/06/2026

Successful trial ✅️ An international team coordinated by #MedUniVienna demonstrated in a #clinicaltrial that #TorqueTenovirus-guided dosing of #immunosuppressants in #kidneytransplant recipients is safe. More about the @ttvguidetx.bsky.social study coordinated by @gregorbond.bsky.social! ⬇️

meduniwien.ac.at

Biomarker-guided immunosuppression following kidney transplantation successfully tested

Further details!

0152

Andreas Kronbichler @kronbichlerlab.bsky.social · 18/05/2026

The issues were created by ChemoCentryx, but Amgen did not take their P4 trial serious! In Europe Avacostar is fully recruited (504 patients). VBDS is not associated with viral infections, I assume, it is a true signal in Japanese

100

Reposted by Andreas Kronbichler

ISNkidneycare @theisn.org · 01/05/2026

📖 This weekend don't miss our @kireports.bsky.social #ISNFridaySelection: Systematic Review of Efficacy and Safety of Avacopan in Real-World Clinical Practice www.kireports.org/article/S2468-024…

062

Reposted by Andreas Kronbichler

Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 18/04/2026

Proposed algorithm for the application of rituximab in minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS) ca. 2020 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/32942039/

054

Andreas Kronbichler @kronbichlerlab.bsky.social · 29/03/2026

It will not be approved outside the US - plus, BAFF/APRIL are more reasonable for patients

111

Andreas Kronbichler @kronbichlerlab.bsky.social · 29/03/2026

Irrelevant drug for 7.95 billion people globally (in this indication)

110

Andreas Kronbichler @kronbichlerlab.bsky.social · 08/03/2026

No, I do not target this! Of course you want serologic remission, but it is not always achievable (and has no major clinical relevance)

120

Andreas Kronbichler @kronbichlerlab.bsky.social · 08/03/2026

I am fan of 6-monthly but only one dose

120

Andreas Kronbichler @kronbichlerlab.bsky.social · 08/03/2026

Yes, would do so; we are starting using it - Allegory data now really show the power of obi

110

Reposted by Andreas Kronbichler

Springer @springer.springernature.com · 17/02/2026

'Rare Kidney Diseases' is a peer-reviewed, #OpenAccess journal dedicated to advancing clinical and translational knowledge in glomerular, autoimmune, and genetic kidney diseases across all age groups. bit.ly/3ZG9FA5 @glomcon.org #NephSky @kronbichlerlab.bsky.social

032

Reposted by Andreas Kronbichler

NEJM.org @nejm.org · 07/01/2026

An 80-year-old man presented with a 4-day history of a rash on his abdomen. Physical examination was notable for periumbilical erythema and a small gray protrusion in the umbilicus. Read the full case details: nej.md/4pYF5NO @i-med.ac.at #MedSky #DermSky

Images in Clinical Medicine
Periumbilical Erythema Migrans

Panel A: A photo of the periumbilical erythema and a small gray protrusion in the umbilicus.
Panels B and C: Photos of a tick being extracted from the umbilicus.

033

Andreas Kronbichler @kronbichlerlab.bsky.social · 22/12/2025

Had a super weird case here once, but agree very unlikely! But she was PR3 sky high

110

Andreas Kronbichler @kronbichlerlab.bsky.social · 22/12/2025

Interesting case, indeed. PR3 in the context of C3G rather uncommon. Undetectable C3 would prompt alternative pathway investigations; also in the consideration cryoglobulins and cryofibrinogen, although C4 reduction would be more common

130

Andreas Kronbichler @kronbichlerlab.bsky.social · 08/10/2025

Pretty much everything was even surprising to us!

110

Andreas Kronbichler @kronbichlerlab.bsky.social · 11/09/2025

Please also look at the Supplements for all the unique features of the case 😉

220

Reposted by Andreas Kronbichler

Kidney International @kidneyint.bsky.social · 11/09/2025

Extrarenal “crescent” in multisystem granulomatosis with polyangiitis doi.org/10.1016/j.kint.2025.03.028 🔹Paravertebral masses in systemic vasculitides such as GPA are rare 🔹This pt had a rupture of the A. colica dextra leading to GI bleeding #MedSky #NephSky @i-med.ac.at @kronbichlerlab.bsky.social

181

Andreas Kronbichler @kronbichlerlab.bsky.social · 13/08/2025

Absolute rarity; only once when the patient was double-positive and the MPO-ANCA became dominant!

100

Andreas Kronbichler @kronbichlerlab.bsky.social · 13/08/2025

Most will eventually turn anti-GBM antibody negative when established on dialysis! Otherwise, you might consider a dose of rituximab

120

Andreas Kronbichler @kronbichlerlab.bsky.social · 13/08/2025

If kidney is lost and no extrarenal manifestation, there would be no indication to use RTX or CYC, right?

240

Reposted by Andreas Kronbichler

Michael Walsh @lastwalsh.bsky.social · 30/07/2025

The International Vasculitis Workshop is coming up! One of my favorite meetings for it's sense of community, and possibilities of forming meaningful collaborations (PEXIVAS was hatched in one of them). Call for early career scientists is here mailchi.mp/icmsaust/ivw...

mailchi.mp

Calling Early Career Scientists and Clinicians

021

Reposted by Andreas Kronbichler

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 15/07/2025

As the quantity of RCTs in nephrology goes up, how is the quality shaping up? CONSORT Reporting standards, ANCA vasculitis edition from @abruch.bsky.social @kronbichlerlab.bsky.social et al in @kireports.bsky.social www.kireports.org/article/S246...

Figure 3 Association of adherence to CONSORT 2010 statement checklist and trial size. Adherence was positively correlated with number of patients enrolled in the trial.

073

Reposted by Andreas Kronbichler

Bryce Barr @brycebarr.bsky.social · 04/07/2025

It was a pleasure to collaborate with @kronbichlerlab.bsky.social and Dr. Astrid Weins on this article. We describe transformations in our understanding of podocytopathies, and novel treatment approaches in light of those advancements. journals.lww.com/co-nephrolhy...

journals.lww.com

New insights into the biology and treatment of minimal... : Current Opinion in Nephrology and Hypertension

sease and focal segmental glomerulosclerosis, there has been a transformation of our understanding of disease pathogenesis and treatment rationale. Recent findings Antinephrin antibodies are common...

061

Andreas Kronbichler @kronbichlerlab.bsky.social · 03/07/2025

I was also there and enjoyed the discussions a lot!

110

Reposted by Andreas Kronbichler

Johann Morelle @johannmorelle.bsky.social · 16/05/2025

Secondary #TMA represent a major unmet medical need. Grateful for the opportunity to review the role of #complement and discuss when to consider complement inhibitors in these dramatic diseases. 🙏 to outstanding co-authors and the #ERA IWG @kronbichlerlab.bsky.social @ndt-era.bsky.social

052

Andreas Kronbichler @kronbichlerlab.bsky.social · 15/05/2025

Understanding the role of anticoagulation in nephrotic syndrome: Please complete this survey - qualtricsxm564785h8t.qualtrics.com/jfe/form/SV_... It takes 5 minutes and is highly appreciated. 10 more responses are needed

qualtricsxm564785h8t.qualtrics.com

Online Survey Software | Qualtrics Survey Solutions

Qualtrics sophisticated online survey software solutions make creating online surveys easy. Learn more about Research Suite and get a free account today.

011

Andreas Kronbichler @kronbichlerlab.bsky.social · 01/04/2025

Don’t forget our podocytopathy study 🤣

120

Reposted by Andreas Kronbichler

NDT @ndt-era.bsky.social · 10/02/2025

Disease-modifying anti-nephropathic drugs (DMANDs) – a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA) doi.org/10.1093/ndt/...

066

Reposted by Andreas Kronbichler

Simone Sanna-Cherchi 🧬 @genetickidneydoc.bsky.social · 28/01/2025

👏👏👏 @kronbichlerlab.bsky.social #FSGS #Nephroticsyndrome #APOL1 just one small note on %FPE/genetics. The concept that genetic forms have ⬇️FPE is confounded. Most FSGS related to slit-diaphragm genes presenting with NS have ⬆️FPE. We see nearly total FPE with TRPC6, INF2, NPHS1, NPHS2, MYO1E et al

092

Andreas Kronbichler @kronbichlerlab.bsky.social · 22/01/2025

Why is rituximab not an option? It is the most effective treatment option. I guess there is no experience combining TAC and AVA so far. But I would contact the company (Amgen/CSL Vifor)

130

Andreas Kronbichler @kronbichlerlab.bsky.social · 15/01/2025

A true group effort and work of 2 years! Hope you are enjoying it!

060

Andreas Kronbichler @kronbichlerlab.bsky.social · 10/01/2025

Phenotypic differences between AAV patients in Japan (compared to USA/EU) are obvious. In this study, we surveyed patients presenting during the early phase of the pandemic. A striking difference in the use of glucocorticoids at 6 months has also been observed! academic.oup.com/rheumatology...

073

Andreas Kronbichler @kronbichlerlab.bsky.social · 30/12/2024

Probably also a scenario where I would prefer EuroLupus CYC over MMF as induction therapy!

161

Reposted by Andreas Kronbichler

Kidney International @kidneyint.bsky.social · 23/12/2024

Sex dimorphism in #kidney health and disease: mechanistic insights and clinical implication doi.org/10.1016/j.kint.2024.08.038 #OpenAccess #KIReview #AKI #acutekidneyinjury #CKD #kidney #autoimmunedisease #NephSky #SkyNeph #MedSky

0112

Andreas Kronbichler @kronbichlerlab.bsky.social · 20/12/2024

Finally, our analysis provides evidence that PR3-ANCA positive patients have a greater likelihood to recover kidney function and the % difference increase was significant!

020

Andreas Kronbichler @kronbichlerlab.bsky.social · 20/12/2024

No difference was seen when we focused on the different GC regimens! That is an important conclusion as recent retrospective data questions the reduced-dose PEXIVAS regimen

110

Andreas Kronbichler @kronbichlerlab.bsky.social · 20/12/2024

Kidney function recovery becomes a relevant endpoint in crescentic GN, which most of us defined as eGFR increase of 15 ml! We see a modest difference between the groups at 52 weeks in favor of PLEX!

100

Andreas Kronbichler @kronbichlerlab.bsky.social · 20/12/2024

In a sub-analysis of the PEXIVAS trial, we analysed eGFR course over the first 52 weeks (www.kidney-international.org/article/S008.... Key: while the initial increase in eGFR is significant (PLEX vs no-PLEX), no major difference is seen at 52 weeks

kidney-international.org

DEFINE_ME

120

Andreas Kronbichler @kronbichlerlab.bsky.social · 19/12/2024

These data are not changing the practice (I would guess). We wanted to give an overview; we are not proposing that people need to be PLEXed or not to be PLEXed based on these results. But we tend to PLEX the younger individuals who will benefit from 2-3 additional ml GFR at w52

230

Andreas Kronbichler @kronbichlerlab.bsky.social · 19/12/2024

No, we defined all analyses a priori. No p-cherry picking as you usually see it. And importantly, these data stem from a clinical trial. Why should an increase of eGFR ≥15 ml/min/1.73 m2 be clinically meaningless. Look at the RaDaR long-term data and risk of ESKD and you will see its importance.

120

Andreas Kronbichler @kronbichlerlab.bsky.social · 19/12/2024

The use of a 15 ml/min/1.73 m2 cut-off to define kidney function recovery was proposed by us and others before and seems to be sensible in AAV. Notably, there was a difference of 8% between groups at week 52 and thus we do believe this represents a clinically meaningful difference.

010

Andreas Kronbichler @kronbichlerlab.bsky.social · 12/12/2024

A call for potential candidates. The YNP of the European Renal Association has launched the list of 2025 mentors for the mentorship program! www.era-online.org/research-edu... I am delighted to work with one mentee for the first time and looking forward to your submission!

era-online.org

YNP Mentorship Programme | ERA

The ERA YNP Mentorship Programme offers an opportunity to exchange knowledge and experience with international colleagues.

021

Andreas Kronbichler @kronbichlerlab.bsky.social · 10/12/2024

Last lab meeting of the year. Those joining virtually were very unlucky today 😍! Thanks to my wonderful Team for a successful year!

040

Andreas Kronbichler @kronbichlerlab.bsky.social · 03/12/2024

@ilayberke.bsky.social @m-windp.bsky.social @saynanorouzi.bsky.social Alongside description of histopathology, we provide typical examples of ANCA-associated GN (especially focusing on crescent formation)

151